When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Smoking cessation

Evidence last reviewed: 22 Oct 2026
Topic last updated: 10 Nov 2026

Summary

Definition

History and exam

Key diagnostic factors

  • number of cigarettes per day
  • time to first cigarette (TTFC)
  • use of alternative tobacco and nicotine delivery products
  • previous quit attempts and cessation interventions
  • history of substance use disorder
  • pregnancy or breastfeeding
Full details

Other diagnostic factors

  • history of depression
  • history of schizophrenia
  • seizure disorder
  • hypertension
  • unstable cardiac disease
  • ventricular arrhythmia
  • asthma
  • chronic obstructive pulmonary disease
  • temporomandibular joint or dental disorder
Full details

Risk factors

  • age <24 years
  • parental smoking
  • low socioeconomic status
  • history of mental illness or substance use disorder
  • history of HIV/AIDS
  • use of alternative tobacco and nicotine delivery products
  • genetics
Full details

Diagnostic tests

1st tests to order

  • self-report of smoking status
  • Fagerström Test For Nicotine Dependence (FTND)
  • Heaviness of Smoking Index (HSI)
Full details

Tests to consider

  • exhaled carbon monoxide monitoring
  • cotinine level
Full details

Treatment algorithm

ACUTE

hospitalized individuals who actively smoke

ONGOING

individuals who are actively smoking and ready to quit: adults (not pregnant/breastfeeding)

individuals who are actively smoking and ready to quit: pregnant/breastfeeding women or adolescents

individuals who are actively smoking and not ready to quit

Contributors

Authors

Samuel Gurevich, MD, FCCP

Pulmonary Department

Director

Respiratory Therapy

Cleveland Clinic

Weston, FL

Disclosures

SG declares that he has no competing interests.

Acknowledgements

Dr Samuel Gurevich would like to gratefully acknowledge Dr Franck F. Rahaghi, Dr Felix Hernandez, Dr Jose Gonzalez, and Dr Theodore W. Marcy, previous contributors to this topic.

Disclosures

FFR is a consultant and speaker for Bayer, United Therapeutics, Janssen-PH, Merck, Boehringer Ingelheim, Takeda, and Talecris. He is involved in industry-sponsored research with Bayer, Janssen-PH, Gossamer Bio, and Bellerophon. FH, JG, and TWM declare that they have no competing interests.

Peer reviewers

Jaymin Morjaria, MBBS, FRCP, MD

Consultant Respiratory Physician

Guy’s and St Thomas NHS Foundation Trust

Harefield Hospital

Middlesex

Honorary Senior Lecturer

Brunel University

London

UK

Disclosures

JM has received honoraria for speaking and financial support to attend meetings/advisory boards from Wyeth, Chiesi, Pfizer, MSD, Boehringer Ingelheim, Teva, GSK/Allen & Hanburys, Napp, Almirall, AstraZeneca, Trudell, Cook Medical, Medela AG, Medtronics, and Novartis. He has been an expert witness in a court case relating to the impact of smoking on illness severity, ITU admissions, and mortality from Covid-19 in South Africa in 2020.

Arran Woodhouse, MSc

Senior Tobacco Programme Manager

North Central London Integrated Care Board

London

UK

Disclosures

AW has been reimbursed by Johnson & Johnson Ltd Nicorette UK Consulting for chairing the Smoking Cessation National Advisory Panel on 1 November 2022. He worked with NICE on the recent Tobacco Guideline (NG209) as a topic expert and as a specialist committee member for the treating dependence Quality Standards Advisory Committee (QS 207). He was appointed as an Expert Adviser for the NICE Centre for Guidelines in February 2023. Previous member of the British Thoracic Society's Tobacco Specialist Advisory Group.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. 2020 [internet publication].Full text  Abstract

Tobacco Use and Dependence Guideline Panel, US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. Rockville (MD): US Department of Health and Human Services; 2008.Full text

World Health Organization. ​WHO clinical treatment guideline for tobacco cessation in adults. Geneva: World Health Organization; 2024.Full text  Abstract

National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Feb 2025 [internet publication].Full text

US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Smoking cessation images
  • Differentials

    • Substance use disorder
    More Differentials
  • Guidelines

    • NCCN clinical practice guidelines in oncology: smoking cessation
    • Canadian Cardiovascular Society clinical practice update on contemporary approaches to smoking cessation
    More Guidelines
  • Patient information

    Quitting smoking

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer